Clinical Study Support, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Nagoya Japan (2004)

Organization Overview

First Clinical Trial
2016
NCT02946671
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

nivolumab (opdivo) (2 trials)

ramucirumab (cyramza) (1 trial)

Drugs in Phase 1 Trials (1)

mogamulizumab (poteligeo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Neoplasms (Phase 1)

Mouth Neoplasms (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3